Clinical Trials - January 14, 2014
Pharmalink completes enrolment of patients into phase IIb clinical study
Pharmalink has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon. Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety of two different doses of Nefecon in 90 IgA nephropathy […]